Title: Effects of Non-Cardiac/Non-neurologic Surgery and Anaesthesia on the CSF Proteome, and Modulation by the APOE Mimetic Peptide CN-105

Authors' names and affiliations: Haotian Zou, PhD[1], Michael W. Lutz, PhD[2,3], Matthew W. Foster, PhD[4,5], Mary Cooter Wright[6], Marlene J. Violette, MS[4], Sheng Luo, PhD[1,3], Daniel Laskowitz[2], Michael J. Devinney, MD PhD[3,6,7], Miles Berger, MD PhD[3,6,7,8*]

for the MARBLE, INTUIT & MADCO-PC Study Teams

[1]Department of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA

[2]Department of Neurology, Duke University School of Medicine, Durham, NC, USA

[3]Duke-UNC Alzheimers Disease Research Center, Duke University Medical Center, Durham, NC, USA

[4]Proteomics and Metabolomics Core Facility, Duke University School of Medicine, Durham, NC, USA

[5]Department of Medicine, Duke University School of Medicine, Durham, NC, USA

[6]Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA

[7]These authors contributed equally to this manuscript and are co-senior authors.

[8]Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine & Stanford Health, Stanford CA, USA.

[*]**Corresponding author:**

Miles Berger, MD

Department of Anesthesiology, Perioperative & Pain Medicine,

Stanford University School of Medicine, Stanford CA, USA

mberger1@stanford.edu

Word counts:

Abstract: 250 (not including subsection headers)

Manuscript: 3167 words total (including section headers)

Intro-331, Methods 715, results 1032, discussion 1085

Keywords: Surgery; CSF; Proteome; APOE; CN-105

Declaration of interests: MB reports receiving legal consulting fees related to postoperative neurocognitive function in older adults. For the remaining authors, no conflicts of interest were declared.

Running title: Human CSF Proteome changes After Surgery

Abstract

Objective: To evaluate the effect of non-cardiac/non-neurologic surgery on the CSF proteome, and the effect of the APOE mimetic peptide CN-105 on postoperative CSF proteome changes.

Methods: We performed mass spectrometry-based proteomics on preoperative and 24 hour postoperative cerebrospinal fluid (CSF) samples from 137 patients (age>60) in the MARBLE trial (ct.gov identifier: NCT03802396), who were randomized to receive APOE mimetic peptide CN-105 (or placebo), and in an independent replication cohort. Linear regression was used to evaluate postoperative changes in CSF protein levels and pathway scores (measured by single-sample gene set enrichment analysis [ssGSEA]), with false discovery rate (FDR)-based multiple comparison correction.

Results: Among 2,086 proteins, 881 (42.2%) showed a change after surgery (p-FDR<0.05), of which 57 proteins (6.4%) showed a log2 fold change >0.5 or <-0.5, and postoperative changes occurred in 1,001 (54.0%) of 1854 pathways (p-FDR<0.05). Similar temporal effects were seen in the majority of these proteins and pathways in the replication cohort. The 5 most significantly upregulated CSF pathways involved smooth muscle cell migration (and its regulation) or apoptotic signaling and regulation (including within endothelial cells). The 5 most significantly downregulated CSF pathways included non-canonical NF-κB signal transduction regulation, leukocyte apoptotic process (and negative regulation of it), and sulfur and proteoglycan metabolic processes. There was no significant CN-105 effect on 24-hour postoperative changes in CSF protein levels or ssGSEA pathway scores (p-FDR>0.05 for all).

Conclusions: Significant postoperative changes occurred in over 40% of proteins and over 50% of pathways in the CSF, most significantly in smooth muscle, endothelial, leukocyte, and apoptosis pathways.

INTRODUCTION

Perioperative care can lead to postoperative neurocognitive complications ranging from postoperative delirium to postoperative neurocognitive disorder and stroke.[1-3] The underlying molecular basis for these disorders is unclear, though inflammation has been postulated to play a key role; this can be examined using pre- and post-operative CSF samples.[4] Indeed, CSF mass spectrometry studies have identified specific protein pathways implicated in Alzheimer's Disease,[5-7] and a pilot mass spectrometry study identified differences in CSF complement pathway levels over time among patients with postoperative cognitive dysfunction.[5] Yet, few if any studies have systematically studied postoperative CSF proteome changes among a large cohort of older non-cardiac/non-neurologic surgery patients, which would be a first step towards understanding what postoperative CNS proteomic changes normally occur, and which might be dysregulated in patients with perioperative neurocognitive disorders.

Additionally, there are clearly some patients who have worse long term cognitive trajectories after surgery, such as those who carry the E4 allele of apolipoprotein E (ie *APOE4*). *APOE4* carriers (versus non-carriers) have worse long term cognitive trajectories in the 5 years following surgery,[8] and *APOE4* carriers who underwent surgery had worse long term cognitive decline than non-*APOE4* carriers who underwent surgery, and as compared to both *APOE4* carriers and non-*APOE4* carriers who did not undergo surgery.[9] *APOE4* carriers have altered CSF levels of inflammation-related proteins such as C-reactive protein (CRP), complement and YKL-40/CH3L1,[10, 11] which may contribute to long term neurocognitive decline. Further, modulating APOE protein signaling with the APOE mimetic penta-peptide CN-105 reduces neuro-inflammation and improved outcomes in mice after multiple types of brain injury.[12, 13] CN-105 was safely administered to humans in a phase I trial,[14] and to older surgical patients in a phase II trial.[15] Thus, here we addressed two questions. First, what are the changes in the CSF proteome from before to 24 hours after a variety of non-cardiac/non-neurologic surgeries in

older adults (ie age ≥ 60 years)? Second, does modulating APOE protein signaling with CN-105

in older patients alter these postoperative CSF protein and/or pathway changes?

METHODS

Study Overview and Intervention

We analyzed CSF samples from the triple-blind randomized phase II trial Modulating APOE to Reduce Brain infLammation and postoperative dElirium (MARBLE), which aimed to evaluate the safety and feasibility of CN-105 for preventing delirium in older adults (age ≥ 60 years) after non-cardiac/neurologic surgery. MARBLE was approved by the Western Institutional Review Board and registered with clinicaltrials.gov prior to study initiation (ct.gov identifier: NCT03802396). MARBLE excluded prisoners, those scheduled to receive chemotherapy with detrimental cognitive effects within 6 weeks following surgery, those unable to undergo a lumbar puncture (due to anticoagulation, severe anxiety, or other contraindication) or inappropriate for inclusion based on principal investigator judgement.

MARBLE participants were randomized to receive either placebo, 0.1 mg/kg, 0.5 mg/kg, or 1 mg/kg of CN-105 every 6 hours, starting just before surgery until 3 days later (for 13 doses maximum). After enrollment, MARBLE patients underwent lumbar punctures for cerebrospinal fluid (CSF) collection (as described[4]) before receiving the first dose of CN-105 or placebo, and again 24 hours after the start of surgery.

Proteomics Data and Study Population

We performed mass spectrometry-based proteomics on CSF samples from all 137 MARBLE participants who underwent preoperative and 24 hour postoperative lumbar punctures; see Supplemental Section 1 for details on CSF proteomic data acquisition and processing. Protein intensities were log2 transformed for normality.

Replication Cohort

To replicate/validate our findings from the MARBLE study CSF samples in an independent cohort, we also analyzed mass spectrometry data from CSF samples obtained before and 24

hours after surgery among 97 patients from the MADCO-PC and INTUIT studies (see Supplemental Section 3- Replication Cohort Description for details).[16, 17] MADCO-PC and INTUIT were approved by the Duke IRB, and registered with clinicaltrials.gov (NCT01993836, NCT03273335). We analyzed the temporal effects of surgery on CSF protein and pathway levels in this replication cohort via the same methods as in the MARBLE cohort.

Statistical Analysis

Missing Data Imputation and Temporal Effects on Protein Intensity and Pathway Enrichment Scores

We imputed missing protein intensities via the random forest method (see Supplemental Section 1), and then examined changes in each CSF protein from the pre-operative to 24-hour postoperative timepoint via univariable linear regression models, with multiple comparison correction using false discovery rate (FDR) across the p-values from the 2,086 CSF proteins, with α=0.05[18]. To rule out the possibility of confounding by baseline patient characteristics or surgery type, we also examined changes in each CSF protein and pathway over this time interval using multivariable adjusted linear regression models.

To analyze the temporal effect of non-cardiac/neurologic surgery on protein pathway enrichment scores, we performed single-sample gene set enrichment analysis (ssGSEA) to provide a pathway enrichment score for each pathway in each CSF sample.[19, 20] We used the Gene Ontology database for biological processes (GO-BP), version 2023.2, and extracted ssGSEA scores from 1854 pathways. We computed the difference between the raw ssGSEA scores at the preoperative and 24 hour postoperative timepoints for each pathway, and modeled these differences via both independent univariable linear regression models and independent multivariable adjusted linear regression models, with FDR adjustment across the 1,854 GO-BP pathways in the analysis.

APOE4 effect on Pre to Postoperative Changes in CSF Protein

In a sensitivity analysis, we examine the effect of *APOE4* carrier status on pre to 24 hr postoperative CSF protein changes via independent linear mixed models with CSF protein levels (pre-operative and 24-hour post-operative) as the dependent variable, for each CSF protein. We included the following covariates: timepoint (pre-operative or 24-hour post-operative), *APOE4* carrier status, interaction between timepoint and *APOE4* carrier status, and a random intercept. We tested the effects of time and *APOE4* carrier status, and their interaction effect.

Unbiased Analysis of CN-105 Effect on Changes in Protein Intensity and Pathway Enrichment Score

We assessed the effect of CN-105 on pre-operative to 24-hour post-operative changes in CSF protein intensity levels and pathway enrichment scores using both univariable and multivariable adjusted linear models, as described above. To assess the effect of CN-105 on pre- to 24-hour post-operative changes in pathway enrichment scores, we first selected pathways that showed a significant change from before to 24 hours after surgery. We fit both univariable and multivariable adjusted linear models for pathway enrichment score temporal change, using a regression coefficient for group (CN-105 vs placebo).

RESULTS

Baseline Characteristics, and Temporal Effects on Protein Intensity and Pathway Enrichment Score in the MARBLE cohort

Table 1 displays the baseline MARBLE cohort characteristics; see Supplemental Figure S1 for CONSORT diagram, and Supplemental Section 1 for the missing data imputation approach and performance. Of 2,086 proteins with a missingness of ≤ 80% at both time points in our MARBLE study mass spectrometry dataset, after FDR adjustment, 881 proteins (42.2%) showed a significant intensity level change from before to 24 hours after non-cardiac/neurologic surgery (Fig 1 for the volcano plot), of which 57 (6.4%) proteins showed a log_2 fold change above 0.5 or below -0.5 (i.e., these 57 proteins showed a moderate to large effect size in the log_2 fold change).[21] Table 2 displays the most significantly up-regulated proteins and down-regulated proteins with log_2 FC above 0.5 or below -0.5, from univariable linear models that assessed protein level changes from before to 24 hours after surgery. The 5 most significantly changed protein levels (by t values) after surgery were FSTL3 (Follistatin Like 3; upregulated), SDF1 (Stromal Cell-Derived Factor 1; downregulated), IBP3 (Insulin-like growth factor-binding protein 3; upregulated), SRGN (Serglycin; upregulated), and SAA1 (Serum amyloid A-1 protein; upregulated). All of these top 5 postoperative protein level changes remained highly significant (with the same directionality) in an FDR-corrected multivariable analysis adjusted for numerous baseline patient characteristics (Supplemental Table S7, Supplemental Data Sheet 10), which rules out the possibility that these postoperative protein level changes were confounded by or dependent on specific patient characteristics. The magnitude of these postoperative CSF protein level changes were also similar across patients who underwent different types of surgery (Supplemental Table S1).

1001 of 1854 pathways (54.0%) showed a significant change (i.e. p-FDR<0.05) in enrichment scores from before to 24 hours after surgery in the MARBLE dataset (Fig 2; Table 3).

Supplemental Tables S2a and S2b list the genes for each pathway that was up- or down-regulated after surgery, respectively. The 5 most significantly upregulated pathways were negative regulation of smooth muscle cell migration, negative regulation of endothelial cell apoptotic process, extrinsic apoptotic signaling pathway via death domain receptors, regulation of extrinsic apoptotic signaling pathway via death domain receptors, and smooth muscle cell migration. The 5 most significantly downregulated pathways were regulation of non-canonical NF κB signal transduction, negative regulation of leukocyte apoptotic process, sulfur compound metabolic process, proteoglycan metabolic process, and leukocyte apoptotic process. All of these top postoperative pathway enrichment score changes (i.e., 10 out of 10 up-regulated pathways, and 10 out of 10 down-regulated pathways) remained highly significant (and in the same direction) in an FDR-corrected multivariable analysis that was adjusted for numerous baseline patient characteristics (Supplemental Table S8, Supplemental Data Sheet 11), which rules out the possibility that these postoperative pathway enrichment score changes were confounded by or dependent on specific patient characteristics.

Unbiased Analysis of APOE4 carrier status and CN-105's effects on Changes in Protein Intensity and Pathway Enrichment Score

After FDR adjustment there was no significant effect of *APOE4* carrier status, and no significant interaction effect of *APOE4* carrier status by time, on CSF protein levels (see Supplemental Section 2 - *ApoE-e4* effect). Thus, *APOE4* carriers (as compared to non-carriers) did not have significant differences in baseline or 24 hour postoperative changes in CSF protein levels.

Next, we examined the effect of treatment with the APOE mimetic peptide CN-105 on postoperative CSF protein and pathway changes (see Supplemental Table S3 for baseline characteristics of MARBLE participants who received CN-105 vs placebo). There was no significant effect of CN-105 on pre-operative to 24-hour post-operative CSF protein intensity level changes in univariable models (Supplemental Fig S2, Table S4) or in multivariable models

adjusted for numerous baseline patient characteristics and surgery type (Supplemental Table S9, Supplemental Data Sheet 12). In univariable models, the TM130 protein showed the largest magnitude upregulation by CN-105 ($\log_2$ FC = 0.74, SE = 0.48, 95% CI = [-0.20, 1.69], Supplemental Excel Sheet 14); and the SAA1 protein showed the largest magnitude down-regulation by CN-105 ($\log_2$ FC = -0.78, SE = 0.27, 95% CI = [-1.30, -0.25]), though neither of these changes were significant after FDR correction. Further, there was no significant effect of CN-105 dose level (0, 0.1, 0.5 or 1 mg/kg) on postoperative protein intensity level changes in univariable or multivariable models (see Supplemental Table S5). There was also no significant effect of CN-105 on postoperative CSF protein pathway enrichment score changes in univariable models (see Supplemental Fig. S3; Table S6) or in multivariable models adjusted for numerous baseline patient characteristics and surgery type (Supplemental Table S10, Supplemental Data Sheet 13).

Results from the Replication Cohort

To corroborate these findings, we examined pre to 24-hour postoperative changes in CSF protein levels in an independent replication cohort of 97 participants from two other studies (see methods for replication cohort description; Supplemental Section 3 for additional replication cohort information). Baseline characteristics of the replication cohort are provided in Supplemental Table S11. The FDR adjustment was applied to the replication cohort, similarly as in the MARBLE cohort. Of the 378 proteins that were significantly upregulated after surgery in the MARBLE cohort (after FDR correction) and detectable in the replication cohort, ~60% (227) were also upregulated postoperatively after FDR correction in the replication cohort (Supplemental Figure S4a). Further, of the 354 proteins that were significantly downregulated after surgery in the MARBLE cohort (after FDR correction) and detectable in the replication cohort, ~34% (121) were also downregulated postoperatively after FDR correction in the independent replication cohort (Supplemental Figure S4b). For the pathway effects, ~40% (166)

pathways were also significantly upregulated and ~30% (126) pathways were also significantly downregulated in the replication cohort (i.e., among the 412 and 410 pathways that were significantly up- or down-regulated in the MARBLE cohort, respectively). Further, there was a high degree of correlation between the effect sizes for, and directionality of, the postoperative changes in both the proteins and the pathways seen in the MARBLE cohort and the replication cohort (Figure 3A, Spearman's rho =0.689 (95% CI: [0.655, 0.721], p<0.001; Figure 3B, Spearman's rho =0.583 (95% CI: [0.549, 0.616], p-value<0.001, respectively).

DISCUSSION

This work demonstrates widespread and significant CSF proteome changes 24 hr after non-cardiac/non-neurologic surgery in a moderate sized cohort of older adults. Further, these postoperative CSF protein and pathway changes remained highly consistent across both univariable and multivariable adjusted analyses (to rule out confounding by patient characteristics or surgery type), and in CSF samples from an independent replication cohort. We identified postoperative changes in numerous CSF proteins and pathways involved in neuroinflammation and immune system activation, particularly in monocyte and neutrophil stress response pathways. We also observed postoperative changes in endothelial, actin and collagen pathways that could allow leukocytes to enter the CNS, and changes consistent with increased postoperative apoptosis of leukocytes, endothelial cells and/or other cell types within the CNS.

Surgical trauma is thought to lead to neuroinflammation via blood brain barrier dysfunction, microglial activation, and neuronal damage.[22] Our results demonstrate substantial changes in CSF proteins within these pathways and processes at 24 hours after surgery. One of the most upregulated CSF proteins after surgery was serum amyloid A1 (SAA1), an acute phase response protein expressed in response to inflammation and tissue injury,[23] such as following surgical stress. SAA1 can cross the blood-brain barrier and cause an increase in the number of microglia and pro-inflammatory factors in the brain,[24, 25] and SAA1 protein levels also significantly increased in the hippocampus after surgery in mice.[25] CSF plasminogen activator inhibitor-1 (PAI-1) levels were also significantly up-regulated following surgery here, consistent with the established role of glucocorticoid stress hormones in shifting the hippocampal balance between expression of Pal-1 and its target, tissue plasminogen activator (tPA).[26] A cellular stress response is also consistent with the postoperative down-regulation of Collagen Type I Alpha 1 Chain (COL1A1) and Collagen Type I Alpha 2 Chain (COL1A2) observed here, since collagen expression by fibroblasts is downregulated by stress-induced adrenal cortisol release

in a dose-dependent manner[27] that can be blocked by glucocorticoid receptor (GR) antagonists.[28] Overall, these data suggest that similar stress-induced protein level changes as those seen in these in non-CNS biological contexts also within the human central nervous system (ie CSF) of older adults following non-cardiac/non-neurologic surgery.

Consistent with the individual postoperative CSF collagen protein level decreases discussed above, the collagen fibril organization pathway was also significantly downregulated after surgery, which may facilitate the entry of peripheral leukocytes and monocytes into the CNS, as seen in both mouse surgical models[29-31] and in older surgical patients.[32] These mouse studies and the postoperative changes in CSF biological pathways described here are consistent with the idea that after surgical stress in older adults, leukocytes migrate from the vascular endothelium, cross blood vessel walls and the surrounding smooth muscle via diapedesis to reach the brain parenchyma and interstitial fluid, which is in equilibrium with the CSF. This process involves actin structure changes within the vascular endothelium, consistent with the postoperative changes in CSF actin filament organization pathways seen here.[33, 34] After entering the central nervous system, these leukocytes (especially neutrophils and monocytes) likely undergo apoptosis due to their known short half-life (6-8 hours for neutrophils[35]), consistent with the postoperative CSF alterations of numerous apoptosis-related pathways observed here.

Indeed, of the top 40 CSF proteomic pathways that we found were upregulated after surgery, 8 (including 4 of the top 5) involved inflammation, immune response, and/or leukocyte/monocyte/neutrophil biology, 4 involved apoptosis, 7 involved wound healing/platelets/coagulation, and 6 involved actin/cytoskeleton biology. Six pathways downregulated after surgery were related to neuronal/synaptic function and development, and 19 were related to general growth/development (including the TGFβ pathway). Taken together, these data fit with a model in which the postoperative activation of inflammatory and stress

pathways leads to decreased tissue development/growth processes (perhaps as a consequence of decreased TGF beta signaling) and decreased synaptic and neuronal function.

This study has several limitations. First, while we detected over 2,000 different CSF proteins, this also increased the burden of false discovery rate-based multiple testing correction, which may have reduced power to detect effects of either CN-105 or *APOE4* on CSF protein or pathway levels. Second, our moderate sample size (137 patients) relative to the number of proteins measured (>2,000) may also explain why we did not detect statistically significant effects (after FDR correction) of CN-105 treatment or *APOE4* carrier status. Thus, the lack of a detectable statistically significant effect of APOE4 on CSF protein levels, or of CN-105 on postoperative protein or pathway changes, should not be viewed as definitive evidence that neither of these effects exists. Third, like all unbiased mass spectrometry-based proteomic studies, the protein intensities studied here are semi-quantitative, not truly quantitative, measurements. Fourth, here we studied CSF proteomic changes at just one postoperative time point (i.e. 24 hours after surgery). A more detailed time course of postoperative CSF protein and pathway changes would provide greater insights into temporal change trajectories, though this would be challenging: it would require multiple postoperative lumbar punctures or intrathecal catheter placements.

This study also has several key strengths. These include: 1) a moderately large cohort of older surgical patients that underwent pre- and 24 hr post-operative lumbar punctures for research, 2) an independent replication cohort of CSF samples from older non-cardiac/non-intracranial surgery patients in other studies that also underwent pre- and 24 hr post-operative lumbar punctures; 3) comprehensive unbiased proteomic analysis and rigorous statistical analyses with FDR-based multiple comparison correction; and 4) pathway analysis using ssGSEA and multivariable models to control for potential confounders and covariates. Finally, a fifth strength of this work is that even though there were significant technical differences in the mass spectroscopy assays used for the MARBLE cohort samples versus the independent

replication cohort samples, we nonetheless observed very similar postoperative changes in CSF protein and pathway levels in both cohorts, providing strong confidence in the overall validity of these results.

This work provides valuable insights into the CSF proteomic and pathway changes that occur in response to surgery in older adults, and represents one of the first systematic and unbiased descriptions of the postoperative molecular changes that take place within the central nervous system of older adults who underwent non-cardiac/non-neurologic surgery. Further, the postoperative protein pathway changes seen here are consistent with prior animal model work and suggest that there is a postoperative leukocyte influx across the neurovascular endothelium into the brain parenchyma, the brain's interstitial fluid and the CSF. Future studies should evaluate the role of these CSF protein and pathway changes in perioperative neurocognitive disorders among older adults, and test whether blocking specific postoperative protein or pathway changes within the human central nervous system helps prevent these disorders.

Collaborators:

The MADCO-PC Study Group Also Includes: Brian E. Brigman, Jeffrey N. Browndyke, W. Michael Bullock, Jessica Carter, Joseph Chapman, Brian Colin, Mary Cooter Wright, Thomas A. D'Amico, James K. DeOrio, Ramon M. Esclamado, Michael N. Ferrandino, Jeffrey Gadsden, Grant E. Garrigues, Stuart Grant, Jason Guercio, Dhanesh Gupta, Ashraf Habib, David H. Harpole, Mathew G. Hartwig, Ehimemen Iboaya, Brant A. Inman, Anver Khan, Sandhya Lagoo-Deenadayalan, Paula S. Lee, Walter T. Lee, John Lemm, Howard Levinson, Christopher Mantyh, Joseph P. Mathew, David L. McDonagh, John Migaly, Suhail K. Mithani, Eugene Moretti, Judd W. Moul, Mark F. Newman, Brian Ohlendorf, Alexander Perez, Andrew C. Peterson, Glenn M. Preminger, Quintin Quinones, Cary N. Robertson, Sanziana A. Roman, Scott Runyon, Aaron Sandler, Faris M. Sbahi, Randall P. Scheri, S. Kendall Smith, Leonard Talbot, Julie K. M. Thacker, Jake Thomas, Betty C. Tong, Steven N. Vaslef, Nathan Waldron, Xueyuan Wang, and Christopher Young.

The INTUIT Study Group Also Includes: Leah Acker, Cindy Louise Amundsen, Oke Anakwenze, Harel Anolick, David Attarian, Pallavi Avasarala, Chakib Ayoub, Matthew Barber, Rachel Beach, Andrew Berchuck, Dan G. Blazer III, Michael Bolognesi, Rachele Brassard, Brian Brigman, William Michael Bullock, Thomas Bunning, Victor Cai, Yee Ching Vanessa Cheong, Soren K Christensen, Brian Colin, Mary Cooter Wright, Mitchell Wayne Cox, Thomas D'Amico, Brittany Anne Davidson, James Keith Deorio, Mark E. Easley, Sarada Eleswarpu, Detlev Erdmann, Mariana Feingold, Michael Nicolo Ferrandino, Jeffrey Gadsden, Mark Gage, Arun Ganesh, Grant Edward Garrigues, Rachel Adams Greenup, Ashraf Habib, Ashley Hall, Rhett K. Hallows, David Harpole Jr, Matthew Hartwig, Laura Havrilesky, Courtney Holland, Scott Thomas Hollenbeck, Thomas Hopkins, Edward Ross Houser ll, Samuel Huang, Ehimemen Iboaya, Brant Inman, William Jiranek, Russel Kahmke, Amie Kawasaki, Brendan Kelleher, Jay Han Kim, Jacob Klapper, Christopher Klifto, Rebecca Klinger, Stuart Knechtle, Sandhya A. Lagoo-

Eugene W. Moretti, Paul J Mosca, Judd W Moul, Thomas L Novick, Steven A Olson, Theodore N Pappas, John J Park, Andrew C Peterson, Brett T Phillips, Thomas J Polascik, Peter Potash, Glenn M Preminger, Rebecca A Previs, Melody Reese Smith, Kenneth Roberts, Cary N Robertson, Frank Rockhold, David Ryu, Charles D Scales Jr, Kevin N Shah, Randall P Scheri, Nazema Y Siddiqui, Shayan Smani, Kevin W Southerland, Michael T Stang, Ayesha Syed, Alicja Szydlowska, Julie K M Thacker, Niccolò Terrando, Noah J. Timko, Yanne Toulgoat-DuBois, Keith W. VanDusen, Anthony G Visco, Alison C Weidner, Marty Woldorff, Mamata Yanamadala, Sabino Zani Jr., and Henrik Zetterberg.

Funding

This work was supported by a Program to Accelerate Clinical Trials Grant from the Alzheimer's Drug Discovery Foundation (to MB), an International Anesthesia Research Society Mentored Research Award (to MB), NIH R01-AG076903 (to MB), NIH R03-AG050918 (to MB), NIH K76-AG057022 (to MB), and a new investigator award by the National Alzheimer's Coordinating Center (to MJD). MB acknowledges additional support from NIH R01-AG073598 (to MB), the Duke/UNC Alzheimer's Disease Research Center (5P30-AG072958, to Drs. Heather E Whitson & Gwenn Garden), and the Duke Pepper Center (5P30-AG028716, to Drs. Ken Schmader & Heather E. Whitson).

Authors' contributions:

Study concept and design: MWL, MWF, MCW, DL, MJD, MB

Proteomic Data Collection: MWF, MJV.

Statistical analysis: HZ, MWL, MWF, SL.

Data interpretation: HZ, MWL, MWF, SL, DL, MJD, MB.

Manuscript preparation: HZ, MWL, MWF, MCW, MJD, MB

Manuscript review and final approval: all authors

Acknowledgements: We thank Drs Beth Stevens, Nader Morshed and Matthew Johnson for helpful comments on this manuscript, and the older surgical patients who participated in the studies that provided the samples for this work.

Supplementary Material

Supplemental Digital Content – Word.docx

Supplemental Digital Content – Excel.xlsx

Supplemental Data.xlsx

REFERENCES

1. Evered L, Silbert B, Knopman DS, et al. Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018. *Anesthesiology* 2018; 129(5):872-879.
2. Berger M, Terrando N, Smith SK, et al. Neurocognitive function after cardiac surgery: from phenotypes to mechanisms. *Anesthesiology* 2018; 129(4):829-851.
3. Vlisides P, Mashour GA. Perioperative stroke. *Can J Anaesth* 2016; 63(2):193.
4. Nobuhara CK, Bullock WM, Bunning T, et al. A protocol to reduce self-reported pain scores and adverse events following lumbar punctures in older adults. *J Neurol* 2020; 267:2002-2006.
5. VanDusen KW, Li Y-J, Cai V, et al. Cerebrospinal fluid proteome changes in older non-cardiac surgical patients with postoperative cognitive dysfunction. *J Alzheimers Dis* 2021; 80(3):1281-1297.
6. Higginbotham LA, Ping L, Dammer EB, et al. Proteomics identifies CSF biomarker panels reflective of pathological networks in the Alzheimer's disease brain: Biomarkers (non☐neuroimaging): Novel biomarkers. *Alzheimers Dement* 2020; 16:e042227.
7. Johnson EC, Dammer EB, Duong DM, et al. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. *Nat Med* 2020; 26(5):769-780.
8. Bartels K, Li Y-J, Li Y-W, et al. Apolipoprotein epsilon 4 genotype is associated with less improvement in cognitive function five years after cardiac surgery: a retrospective cohort study. *Canadian journal of anaesthesia= Journal canadien d'anesthesie* 2015; 62(6):618.
9. Schenning KJ, Murchison CF, Mattek NC, et al. Surgery is associated with ventricular enlargement as well as cognitive and functional decline. *Alzheimer's & Dementia* 2016; 12(5):590-597.
10. Berger M, Cooter M, Roesler AS, et al. APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid 1. *J Alzheimers Dis* 2021; 79(2):511-530.
11. Ayton S, Janelidze S, Roberts B, et al. Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age. *Prog Neurobiol* 2021; 198:101904.
12. Lei B, James ML, Liu J, et al. Neuroprotective pentapeptide CN-105 improves functional and histological outcomes in a murine model of intracerebral hemorrhage. *Sci Rep* 2016; 6(1):34834.
13. Laskowitz DT, Van Wyck DW. ApoE mimetic peptides as therapy for traumatic brain injury. *Neurotherapeutics* 2023; 20(6):1496-1507.
14. Guptill JT, Raja SM, Boakye☐Agyeman F, et al. Phase 1 randomized, double☐blind, placebo☐controlled study to determine the safety, tolerability, and pharmacokinetics of a single escalating dose and repeated doses of CN☐105 in healthy adult subjects. *The Journal of Clinical Pharmacology* 2017; 57(6):770-776.
15. Timko NJ, Cooter Wright M, Reese M, et al. The ApoE Mimetic Peptide CN-105 in Older Surgical Patients: The MARBLE Phase 2 Randomized Clinical Trial. *JAMA Surgery* 2025; Under Review.

16. Berger M, Oyeyemi D, Olurinde MO, et al. The INTUIT study: investigating neuroinflammation underlying postoperative cognitive dysfunction. *J Am Geriatr Soc* 2019; 67(4):794-798.
17. Berger M, Browndyke JN, Cooter Wright M, et al. Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers. *Ann Clin Transl Neurol* 2022; 9(2):155-170.
18. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. *Annals of statistics* 2001:1165-1188.
19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci* 2005; 102(43):15545-15550.
20. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature* 2009; 462(7269):108-112.
21. Schork K, Podwojski K, Turewicz M, et al. Important issues in planning a proteomics experiment: statistical considerations of quantitative proteomic data. Quantitative Methods in Proteomics: Springer; 2021:pp. 1-20.
22. Alam A, Hana Z, Jin Z, et al. Surgery, neuroinflammation and cognitive impairment. *EBioMedicine* 2018; 37:547-556.
23. Sun L, Ye RD. Serum amyloid A1: Structure, function and gene polymorphism. *Gene* 2016; 583(1):48-57.
24. Gao Y, Tang S, Liu J, et al. The Administration of Circulating Extracellular Vesicles Modified by Anesthesia and Surgery Induces Delirium-Like Behaviors in Aged Mice. *CNS Neurosci Ther* 2025; 31(6):e70483.
25. Jang WY, Lee BR, Jeong J, et al. Overexpression of serum amyloid a 1 induces depressive-like behavior in mice. *Brain Res* 2017; 1654(Pt A):55-65.
26. Mennesson M, Revest JM. Glucocorticoid-Responsive Tissue Plasminogen Activator (tPA) and Its Inhibitor Plasminogen Activator Inhibitor-1 (PAI-1): Relevance in Stress-Related Psychiatric Disorders. *Int J Mol Sci* 2023; 24(5).
27. Chae M, Bae IH, Lim SH, et al. AP Collagen Peptides Prevent Cortisol-Induced Decrease of Collagen Type I in Human Dermal Fibroblasts. *Int J Mol Sci* 2021; 22(9).
28. Mi Y, Wang W, Zhang C, et al. Autophagic Degradation of Collagen 1A1 by Cortisol in Human Amnion Fibroblasts. *Endocrinology* 2017; 158(4):1005-1014.
29. Yang T, Xu G, Newton P, et al. Maresin 1 attenuates neuroinflammation in a mouse model of perioperative neurocognitive disorders. *Br J Anaesth* 2019; 122(3):350-360.
30. Terrando N, Eriksson LI, Kyu Ryu J, et al. Resolving postoperative neuroinflammation and cognitive decline. *Ann Neurol* 2011; 70(6):986-995.
31. Hirsch J, Vacas S, Terrando N, et al. Perioperative cerebrospinal fluid and plasma inflammatory markers after orthopedic surgery. *J Neuroinflammation* 2016; 13:1-12.
32. Berger M, Murdoch DM, Staats JS, et al. Flow cytometry characterization of cerebrospinal fluid monocytes in patients with postoperative cognitive dysfunction: a pilot study. *Anesthesia & Analgesia* 2019; 129(5):e150-e154.
33. Heemskerk N, Schimmel L, Oort C, et al. F-actin-rich contractile endothelial pores prevent vascular leakage during leukocyte diapedesis through local RhoA signalling. *Nat Commun* 2016; 7(1):10493.

34.   Wójciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. *J Cell Biol* 1999; 145(6):1293.

35.   Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. *Trends Immunol* 2010; 31(8):318-24.

Tables

Table 1. Baseline characteristics of the 137* MARBLE study participants with preoperative and 24 hr postoperative CSF samples. The numbers are presented as mean (sd) or count (percentage).

Baseline Patient Characteristic	Value
Age	68.9 (5.0)
Sex	
Male	89 (65.0%)
Female	48 (35.0%)
Education (years)	16.3 (3.4)
Race	
Caucasian/White	118 (86.1%)
Black or African American	10 (7.3%)
Asian	2 (1.5%)
American Indian or Alaska Native	3 (2.2%)
Other/Unknown	4 (2.9%)
ApoE-e2 **copy number**	
0	122 (89.1%)
1	14 (10.2%)
2	1 (0.7%)
ApoE-e4 copy number	
0	99 (72.3%)

1	35 (25.5%)
2	3 (2.2%)
BMI	29.7 (5.0)
Surgery type	
Thoracic Surgery	9 (6.6%)
General Surgery	20 (14.6%)
Gynecologic Surgery	7 (5.1%)
Orthopedics Surgery	52 (38.0%)
ENT Surgery	7 (5.1%)
Plastic Surgery	5 (3.6%)
Urologic Surgery	37 (27.0%)
ASA physical status classification	
1	1 (0.7%)
2	47 (34.3%)
3	88 (64.2%)
4	1 (0.7%)

* See Supplemental Table S3 for the baseline characteristics of the participants in the placebo group and CN-105 group.

Table 2. The 10 up-regulated and 8 down-regulated proteins (sorted by p-value) from univariable linear models (t-tests) that assessed changes in CSF protein levels from before to 24 hours after surgery in the MARBLE patient cohort, with a log2 fold change above 0.5 or below -0.5 (i.e., these proteins show moderate to large effects). Positive fold change values (Log_2FC) indicate an increase in the given protein level from before to 24 hours after surgery, and *vice versa*.

Up-regulated proteins		Log_2 FC	Std.Err	95% CI	t	p-value	Adj.P
FSTL3	Follistatin-related protein 3	0.884	0.033	(0.819, 0.949)	26.608	9.14E-56	9.54E-53
IBP3	Insulin-like growth factor-binding protein 3	0.557	0.029	(0.500, 0.614)	19.323	8.00E-41	1.85E-38
SRGN	Serglycin	0.809	0.042	(0.727, 0.891)	19.081	2.80E-40	5.85E-38
SAA1	Serum amyloid A-1 protein	2.255	0.122	(2.016, 2.494)	18.436	8.27E-39	1.44E-36
AGRG1	Adhesion G-protein coupled receptor G1	0.773	0.042	(0.691, 0.855)	18.361	1.23E-38	1.97E-36
TSK	Tsukushin	0.968	0.060	(0.850, 1.086)	16.036	3.77E-33	4.14E-31
IBP1	Insulin-like growth factor-binding protein 1	0.990	0.067	(0.859, 1.121)	14.756	5.09E-30	3.94E-28
PAI1	Plasminogen activator inhibitor 1	1.589	0.108	(1.377, 1.801)	14.741	5.56E-30	4.15E-28
TIMP4	Metalloproteinase inhibitor 4	0.714	0.049	(0.618, 0.810)	14.705	6.83E-30	4.91E-28
WDR1	WD repeat-containing protein 1	0.743	0.056	(0.633, 0.853)	13.204	3.91E-26	2.20E-24
Down-regulated proteins		**Log_2 FC**	**Std.Err**	**95% CI**	**T**	**p-value**	**Adj.P**
SDF1	Stromal cell-derived factor 1	-0.776	0.034	(-0.843, -0.709)	-22.489	1.16E-47	4.85E-45
CCL19	C-C motif chemokine 19	-0.878	0.079	(-1.033, -0.723)	-11.104	8.63E-21	3.00E-19
ESM1	Endothelial cell-specific molecule 1	-0.645	0.075	(-0.792, -0.498)	-8.580	1.90E-14	3.61E-13
CXL10	C-X-C motif chemokine 10	-0.597	0.074	(-0.742, -0.452)	-8.019	4.38E-13	7.24E-12
MCH	Pro-MCH	-0.606	0.107	(-0.816, -0.396)	-5.680	7.83E-08	6.66E-07
ZC3H1	Zinc finger C3H1 domain-containing protein	-0.689	0.160	(-1.003, -0.375)	-4.309	3.12E-05	1.74E-04
PAP1L	Polyadenylate-binding protein 1-like	-0.601	0.151	(-0.897, -0.305)	-3.989	1.08E-04	5.24E-04

NPS3A	Protein NipSnap homolog 3A	-0.550	0.183	(-0.909, -0.191)	-2.999	3.22E-03	1.06E-02

* Abbreviations: Std.Err: standard error; Adj.P: adjusted p-value. FC: fold change. CI: confidence interval.

* See Supplemental Table S7 for multivariable model adjusted for CN-105, age, sex, education years, *ApoE*-e2 copy number, *ApoE*-e4 copy number, BMI, surgery type, ASA physical status classification, and baseline protein intensity.

Table 3. The 10 up-regulated and 10 down-regulated pathways (sorted by p-value) from the

univariable linear models that assessed the temporal effect of the pathway enrichment score

from before to 24 hours after surgery, based on the Gene Ontology database for biological

processes (GO-BP) in the MARBLE cohort. The top panel displays pathways that are the most

highly up-regulated; the bottom panel displays pathways that are the most down-regulated. Beta

coefficients are from linear models that assessed the effect of time (ie from before to 24 hrs

after anesthesia and surgery) on the ssGSEA enrichment scores.

Up-regulated pathways	Beta	Std.Err	95% CI	t	p-value	Adj.P
negative regulation of smooth muscle cell migration	77.574	4.183	(69.375, 85.773)	18.547	4.60E-39	8.53E-36
negative regulation of endothelial cell apoptotic process	93.981	5.417	(83.364, 104.598)	17.349	2.76E-36	2.56E-33
extrinsic apoptotic signaling pathway via death domain receptors	67.583	4.641	(58.487, 76.679)	14.563	1.54E-29	9.49E-27
regulation of extrinsic apoptotic signaling pathway via death domain receptors	79.959	5.556	(69.069, 90.849)	14.392	4.08E-29	1.89E-26
smooth muscle cell migration	40.878	3.068	(34.865, 46.891)	13.323	1.96E-26	7.28E-24
regulation of fibrinolysis	43.100	3.474	(36.291, 49.909)	12.407	4.10E-24	1.27E-21
muscle cell migration	35.009	2.883	(29.358, 40.660)	12.144	1.92E-23	5.08E-21
endothelial cell apoptotic process	61.060	5.199	(50.870, 71.250)	11.744	2.01E-22	4.65E-20
angiogenesis involved in wound healing	67.270	5.860	(55.784, 78.756)	11.480	9.48E-22	1.95E-19
actin filament organization	36.949	3.245	(30.589, 43.309)	11.386	1.65E-21	3.05E-19
Down-regulated pathways	Beta	Std.Err	95% CI	t	p-value	Adj.P
regulation of non-canonical NF κB signal transduction	-50.390	4.940	(-60.072, -40.708)	-10.200	1.71E-18	1.98E-16
negative regulation of leukocyte apoptotic process	-63.415	6.381	(-75.922, -50.908)	-9.938	7.86E-18	7.28E-16
sulfur compound metabolic process	-25.949	2.638	(-31.119, -20.779)	-9.836	1.42E-17	1.16E-15

proteoglycan metabolic process	-36.575	3.801	(-44.025, -29.125)	-9.623	4.88E-17	3.77E-15
leukocyte apoptotic process	-46.150	4.912	(-55.778, -36.522)	-9.395	1.82E-16	1.13E-14
neuron projection extension involved in neuron projection guidance	-42.305	4.533	(-51.190, -33.420)	-9.333	2.61E-16	1.55E-14
regulation of leukocyte apoptotic process	-48.549	5.204	(-58.749, -38.349)	-9.328	2.67E-16	1.55E-14
response to chemokine	-61.512	6.609	(-74.466, -48.558)	-9.307	3.03E-16	1.66E-14
glycoprotein metabolic process	-28.814	3.155	(-34.998, -22.630)	-9.131	8.29E-16	3.94E-14
negative regulation of axon extension involved in axon guidance	-43.733	4.843	(-53.225, -34.241)	-9.030	1.48E-15	6.39E-14

* Abbreviations: Std.Err: standard error; Adj.P: adjusted p-value. CI: confidence interval.

* See Supplemental Table S8 for multivariable model adjusted for CN-105, age, sex, education years, *ApoE*-e2 copy number, *ApoE*-e4 copy number, BMI, surgery type, ASA physical status classification, and baseline enrichment score.

Figure Legends

Fig 1. Volcano plot for the effect of time on CSF protein levels in the MARBLE cohort. The x-axis is the $\log_2$ fold change of the univariate differences in protein intensity levels from before to 24 hours after surgery. The y-axis is the $-\log_{10}$ base adjusted p-value. The horizontal dashed line indicates $-\log_{10}$ base adjusted p-value of 0.05. The vertical dashed lines indicate $\log_2$ fold change threshold of 0.5 and -0.5 (i.e., these proteins show moderate to large effects). The 10 up-regulated proteins and 8 down-regulated proteins sorted by p-values and $\log_2$ fold change threshold above 0.5 or below -0.5 are labelled below.

Fig 2. Volcano Plot for the univariate effect of time on CSF protein pathways in the MARBLE cohort, using the GO database for biological processes (GO-BP). The horizontal dashed line indicates $-\log_{10}$ base adjusted p-value of 0.05. The pathways with top 10 p-values are labelled below.

Figure 3: Spearman's correlations (with 95% confidence interval) between postoperative changes in proteins and pathways between the MARBLE and replication cohorts. A) Scatterplot of the log2 FC of the 800 proteins (A) that showed a significant temporal effect in at least one cohort (426 up-regulated proteins and 374 down-regulated proteins). The diagonal dashed line is the identity line. B) Scatterplot of enrichment score changes for 900 CSF pathways that showed an FDR-significant change from before to 24 hours after surgery at least one cohort (450 up-regulated pathways and 450 down-regulated pathways). The diagonal dashed line is the identity line. In both panels, red dots indicate proteins or pathways that were up- or down-regulated in both cohorts; green dots indicate proteins or pathways that were up- or down-regulated in the MARBLE cohort only; blue dots indicate proteins or pathways that were up- or down-regulated in the Replication cohort only. ES: Enrichment Score.